Compare ACEL & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACEL | KALV |
|---|---|---|
| Founded | 2009 | N/A |
| Country | United States | United States |
| Employees | 1600 | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 948.2M | 1.0B |
| IPO Year | 2017 | 2014 |
| Metric | ACEL | KALV |
|---|---|---|
| Price | $11.65 | $26.79 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $14.67 | ★ $32.60 |
| AVG Volume (30 Days) | 296.4K | ★ 5.4M |
| Earning Date | 05-05-2026 | 07-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 46.34 | N/A |
| EPS | ★ 0.17 | N/A |
| Revenue | N/A | ★ $50,000,000.00 |
| Revenue This Year | $7.07 | $185.42 |
| Revenue Next Year | $2.81 | $59.23 |
| P/E Ratio | $68.47 | ★ N/A |
| Revenue Growth | N/A | ★ 495.66 |
| 52 Week Low | $9.55 | $9.83 |
| 52 Week High | $13.31 | $26.85 |
| Indicator | ACEL | KALV |
|---|---|---|
| Relative Strength Index (RSI) | 47.34 | 74.68 |
| Support Level | $10.86 | $14.25 |
| Resistance Level | $12.57 | $26.85 |
| Average True Range (ATR) | 0.36 | 0.07 |
| MACD | -0.03 | -0.22 |
| Stochastic Oscillator | 34.69 | 71.05 |
Accel Entertainment Inc is a distributed gaming and local entertainment operator in the United States. It is engaged in the installation, maintenance, operation, and servicing of gaming terminals and related equipment, redemption devices that disburse winnings and contain automated teller machine (ATM) functionality, and amusement devices in authorized non-casino locations such as restaurants, bars, convenience stores, liquor stores, truck stops, and grocery stores. The Company also operates stand-alone ATMs in gaming and non-gaming locations. It generates revenue from Net gaming, Amusement, Manufacturing, ATM fees, and others.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.